Find out everything you need to know about the latest COVID-19 booster shot here >

Showing 1 - 6 of 6 Digestive System Diseases
A Phase I/II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma). Subjects will be treated ... Read more >

A Study of Zolbetuximab Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoemboli ... Read more >

KOWA K-877-302

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator:

Phone:

In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >

Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcome ... Read more >